pioglitazone


Also found in: Medical, Wikipedia.

pi·o·glit·a·zone

 (pī′ō-glĭt′ə-zōn′)
n.
A thiazolidinedione drug, C19H20N2O3S, used in its hydrochloride form to treat type 2 diabetes.

[pio-, origin unknown + -glitazone, thiazolidinedione suff.; see rosiglitazone.]
Translations

pioglitazone

n pioglitazona
References in periodicals archive ?
Second Study Indicates No Increased Risk of Bladder Cancer in Patients Treated With Pioglitazone, Further Reinforcing the Positive Benefit/Risk Profile
An analysis of more than 160,000 British diabetics found that those taking either rosiglitazone or pioglitazone had a 28 percent lower incidence of Parkinson's than people taking other diabetes treatments.
The magnitude of the effect of vitamin E on NASH was comparable to pioglitazone, metformin, and obeticholic acid," Dr.
On 10 April 2014, US Food and Drug Administration (USFDA), sanctioned Lupin to sell off generic diabetes management drug Pioglitazone tablets in the American market.
The objective of the present investigation is mainly to evaluate the anti-diabetic activity of embelin in HFD + STZ induced diabetic rat model and compared with pioglitazone, a derivative of thiazolidinediones and, a new generation anti-diabetic drug clinically used in the management of diabetes mellitus (type 2 diabetes).
Linagliptin was administered orally once a day in all cases, either on its own, or in combination with metformin or metformin plus a sulphonylurea or pioglitazone.
Scientists from the University of Alberta have found that pioglitazone, a drug used to treat type 2 diabetes, increases the risk of bladder cancer.
Type 2 diabetes sufferers who use pioglitazone every day for more than two years double their chances of developing the disease, say scientists.
As a result, pioglitazone reduces insulin resistance in liver and peripheral tissues; decreases withdrawal of glucose from the liver; hence reducing the load of glucose, insulin and glycosylated hemoglobin ([HbA.
A recent clinical trial of vitamin E versus the prescription drug pioglitazone (Actos[R]) provided some compelling results, and serves as an excellent introduction to a broader examination of the most promising, safe, low-cost interventions.
Rosiglitazone and pioglitazone are both associated with an increased risk of fracture in postmenopausal women with type 2 diabetes, according to a matched case-control study that used data from the Translating Research into Action for Diabetes (TRIAD) trial.